Your browser doesn't support javascript.
loading
Impact of Hepatic Encephalopathy on Clinical Characteristics and Adverse Outcomes in Prospective and Multicenter Cohorts of Patients With Acute-on-Chronic Liver Diseases.
Long, Liyuan; Li, Hai; Deng, Guohong; Wang, Xianbo; Lu, Sihong; Li, Beiling; Meng, Zhongji; Gao, Yanhang; Qian, Zhiping; Liu, Feng; Lu, Xiaobo; Ren, Haotang; Shang, Jia; Li, Hai; Wang, Shaoyang; Zheng, Yubao; Yan, Huadong; Yin, Shan; Tan, Wenting; Zhang, Qun; Zheng, Xin; Chen, Jinjun; Luo, Sen; Zhao, Jinming; Yuan, Wei; Li, Tao; Zheng, Rongjiong; Liu, Junping; Liu, Xiaoxiao; Gu, Wenyi; Li, Sumeng; Mei, Xue; Chen, Ruochan; Huang, Yan.
Afiliação
  • Long L; Department of Infectious Diseases, Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, Changsha, China.
  • Li H; Department of Gastroenterology, School of Medicine, Ren Ji Hospital, Shanghai Jiao Tong University, Shanghai, China.
  • Deng G; Key Laboratory of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, Chinese Ministry of Health (Shanghai Jiao Tong University), Shanghai, China.
  • Wang X; Chinese Chronic Liver Failure (CLIF) Consortium, Shanghai, China.
  • Lu S; Chinese Chronic Liver Failure (CLIF) Consortium, Shanghai, China.
  • Li B; Department of Infectious Diseases, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
  • Meng Z; Chinese Chronic Liver Failure (CLIF) Consortium, Shanghai, China.
  • Gao Y; Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Qian Z; Department of Infectious Diseases, Institute of Infection and Immunology, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, China.
  • Liu F; Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Lu X; Chinese Chronic Liver Failure (CLIF) Consortium, Shanghai, China.
  • Ren H; Department of Infectious Diseases, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
  • Shang J; Chinese Chronic Liver Failure (CLIF) Consortium, Shanghai, China.
  • Li H; Department of Hepatology, The First Hospital of Jilin University, Changchun, China.
  • Wang S; Chinese Chronic Liver Failure (CLIF) Consortium, Shanghai, China.
  • Zheng Y; Department of Liver Intensive Care Unit, Shanghai Public Health Clinical Centre, Fudan University, Shanghai, China.
  • Yan H; Chinese Chronic Liver Failure (CLIF) Consortium, Shanghai, China.
  • Yin S; Department of Hepatology, Tianjin Institute of Hepatology, Nankai University Second People's Hospital, Tianjin, China.
  • Tan W; Department of Infectious Diseases and Hepatology, The Second Hospital of Shandong University, Jinan, China.
  • Zhang Q; Chinese Chronic Liver Failure (CLIF) Consortium, Shanghai, China.
  • Zheng X; Infectious Disease Center, The First Affiliated Hospital of Xinjiang Medical University, Ürümqi, China.
  • Chen J; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Luo S; Department of Infectious Diseases, Henan Provincial People's Hospital, Zhengzhou, China.
  • Zhao J; Department of Infectious Diseases, Affiliated Hospital of Logistics University of People's Armed Police Force, Tianjin, China.
  • Yuan W; Department of Infectious Diseases, Fuzhou General Hospital of Nanjing Military Command, Fuzhou, China.
  • Li T; Chinese Chronic Liver Failure (CLIF) Consortium, Shanghai, China.
  • Zheng R; Department of Infectious Diseases, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Liu J; Chinese Chronic Liver Failure (CLIF) Consortium, Shanghai, China.
  • Liu X; Department of Hepatology, Ningbo No. 2 Hospital, Ningbo, China.
  • Gu W; Department of Gastroenterology, School of Medicine, Ren Ji Hospital, Shanghai Jiao Tong University, Shanghai, China.
  • Li S; Key Laboratory of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, Chinese Ministry of Health (Shanghai Jiao Tong University), Shanghai, China.
  • Mei X; Department of Infectious Diseases, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
  • Chen R; Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Huang Y; Chinese Chronic Liver Failure (CLIF) Consortium, Shanghai, China.
Front Med (Lausanne) ; 8: 709884, 2021.
Article em En | MEDLINE | ID: mdl-34409052
ABSTRACT
Importance Hepatic encephalopathy is a severe complication, and its contribution to clinical adverse outcomes in patients with acute-on-chronic liver diseases from the East is unclear.

Objective:

We aimed to investigate the impact of hepatic encephalopathy on clinical characteristics and adverse outcomes in prospective and multicenter cohorts of patients with acute-on-chronic liver diseases.

Design:

We conducted a cohort study of two multicenter prospective cohorts.

Setting:

China.

Participants:

Acute-on-chronic liver disease patients with various etiologies. Exposure The diagnosis and severity of hepatic encephalopathy were assessed using the West Haven scale. Main Outcome

Measure:

The correlation between clinical adverse outcomes and varying hepatic encephalopathy grades was analyzed in the target patients.

Results:

A total of 3,949 patients were included, and 340 of them had hepatic encephalopathy. The incidence of hepatic encephalopathy was higher in patients with alcohol consumption (9.90%) than in those with hepatitis B virus infection (6.17%). The incidence of 28- and 90-day adverse outcomes increased progressively from hepatic encephalopathy grades 1-4. Logistic regression analysis revealed that hepatic encephalopathy grades 3 and 4 were independent risk factors for the 28- and 90-day adverse outcome in the fully adjusted model IV. Stratified analyses showed similar results in the different subgroups. Compared to grades 1-2 and patients without hepatic encephalopathy, those with grade 3 hepatic encephalopathy had a significant increase in clinical adverse outcomes, independent of other organ failures. Conclusions and Relevance Hepatic encephalopathy grades 3-4 were independent risk factors for 28- and 90-day adverse outcomes. Hepatic encephalopathy grade 3 could be used as an indicator of brain failure in patients with acute-on-chronic liver disease.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article